Երկիր: Իռլանդիա
Լեզու: անգլերեն
Աղբյուրը: HPRA (Health Products Regulatory Authority)
Eprosartan mesylate
Teva B.V.
C09CA; C09CA02
Eprosartan mesylate
600 milligram(s)
Film-coated tablet
Oral use
Pack sizes of 4, 7, 14, 28, 50, 56, 98 and 280 film-coated tablets.
Product subject to prescription which may be renewed (B)
Angiotensin II antagonists, plain.
Angiotensin II antagonists, plain; eprosartan
It is indicated in adults for the treatment of essential hypertension.
Not marketed
2015-05-29
PACKAGE LEAFLET: INFORMATION FOR THE USER EPROSARTAN TEVA 300 MG FILM-COATED TABLETS EPROSARTAN TEVA 400 MG FILM-COATED TABLETS EPROSARTAN TEVA 600 MG FILM-COATED TABLETS Eprosartan READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Eprosartan Teva is and what it is used for 2. What you need to know before you take Eprosartan Teva 3. How to take Eprosartan Teva 4. Possible side effects 5. How to store Eprosartan Teva 6. Contents of the pack and other information 1. WHAT EPROSARTAN TEVA IS AND WHAT IT IS USED FOR Eprosartan Teva contains the active substance eprosartan. Eprosartan belongs to a group of medicines called ‘angiotensin II receptor antagonists’. It blocks the action of a substance in your body called ‘angiotensin II’. This substance causes your blood vessels to narrow. This makes it more difficult for the blood to flow through the vessels and so your blood pressure increases. By blocking this substance, the vessels relax and your blood pressure decreases. Eprosartan is used to treat high blood pressure (hypertension). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE EPROSARTAN TEVA _ _ DO NOT TAKE EPROSARTAN TEVA: - if you are allergic to eprosartan or any of the other ingredients of this medicine (listed in Section 6). - if you have SEVERE liver disease. - if you have SEVERE problems with the blood flow in your kidneys or serious restriction to blood flow_ _in a single functioning kidney. - if you are more than 3 months pregnant (it is also better to avoid eprosartan in early pregnancy Կարդացեք ամբողջական փաստաթուղթը
Health Products Regulatory Authority 02 November 2020 CRN00C0GD Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Eprosartan Teva 600 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 735.84 mg eprosartan mesilate equivalent to 600 mg eprosartan. Excipient(s) with known effect: 43 mg lactose monohydrate per tablet. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White, capsule shaped, biconvex film-coated tablets. Tablets are approximately 20 x 9 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Eprosartan is indicated in adults for the treatment of essential hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 600 mg eprosartan once daily. Achievement of maximal blood pressure reduction in most patients may take 2 to 3 weeks of treatment. Eprosartan may be used alone or in combination with other anti-hypertensives (see sections 4.3, 4.4, 4.5 and 5.1). In particular, addition of a thiazide-type diuretic such as hydrochlorothiazide or a calcium channel blocker such as sustained release nifedipine has been shown to have an additive effect with eprosartan. Duration of treatment is not limited. _Older people_ No dose adjustment is required in older people. _Patients with Hepatic impairment_ There is limited experience in patients with hepatic insufficiency _(see section 4.3, Contraindications)_. _Patients with Renal impairment_ In patients with moderate or severe renal impairment (creatinine clearance <60 ml/min), the daily dose should not exceed 600 mg. _Paediatric population_ Eprosartan Teva 600 mg Film-coated Tablets are not recommended for use in children and adolescents. The safety and efficacy of eprosartanin children and adolescents under 18 years have not been established. No data are available. Method of administration Oral use. Eprosartan may be taken with or without food. Health Products Regulatory Authority 02 November 2020 CRN00C0GD Page 2 of 9 Կարդացեք ամբողջական փաստաթուղթը